ES2932370T3 - Compuestos con actividad inhibidora de la polimerización de la tubulina y con propiedades inmunomoduladoras - Google Patents

Compuestos con actividad inhibidora de la polimerización de la tubulina y con propiedades inmunomoduladoras Download PDF

Info

Publication number
ES2932370T3
ES2932370T3 ES19733845T ES19733845T ES2932370T3 ES 2932370 T3 ES2932370 T3 ES 2932370T3 ES 19733845 T ES19733845 T ES 19733845T ES 19733845 T ES19733845 T ES 19733845T ES 2932370 T3 ES2932370 T3 ES 2932370T3
Authority
ES
Spain
Prior art keywords
group
alkyl group
hydrogen atom
compound
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19733845T
Other languages
English (en)
Spanish (es)
Inventor
Mouad Alami
Olivier Provot
Abdallah Hamze
Ilhem Khelifi
Timothée Naret
Sébastien Apcher
Romain Darrigrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Original Assignee
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Institut National de la Santé et de la Recherche Médicale
Université Paris-Saclay
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut Gustave Roussy, Institut National de la Santé et de la Recherche Médicale, Université Paris-Saclay filed Critical Centre National de la Recherche Scientifique
Application granted granted Critical
Publication of ES2932370T3 publication Critical patent/ES2932370T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
ES19733845T 2018-04-27 2019-04-26 Compuestos con actividad inhibidora de la polimerización de la tubulina y con propiedades inmunomoduladoras Active ES2932370T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1853709A FR3080620B1 (fr) 2018-04-27 2018-04-27 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
PCT/FR2019/050982 WO2019207257A1 (fr) 2018-04-27 2019-04-26 Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices

Publications (1)

Publication Number Publication Date
ES2932370T3 true ES2932370T3 (es) 2023-01-18

Family

ID=63036097

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19733845T Active ES2932370T3 (es) 2018-04-27 2019-04-26 Compuestos con actividad inhibidora de la polimerización de la tubulina y con propiedades inmunomoduladoras

Country Status (9)

Country Link
US (2) US11634405B2 (enExample)
EP (1) EP3784662B1 (enExample)
JP (1) JP7408894B2 (enExample)
AU (1) AU2019259112B2 (enExample)
CA (1) CA3097622A1 (enExample)
DK (1) DK3784662T3 (enExample)
ES (1) ES2932370T3 (enExample)
FR (1) FR3080620B1 (enExample)
WO (1) WO2019207257A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111825610B (zh) * 2020-06-24 2023-03-31 中国药科大学 一种具有抗肿瘤活性的2-甲基喹啉类衍生物及其合成方法和用途
CN115417860B (zh) * 2020-08-03 2023-10-20 中国药科大学 一种具有抗肿瘤活性的喹唑啉类衍生物及其合成方法和用途
CN113173915B (zh) * 2021-03-29 2022-12-09 中南大学湘雅医院 抗皮肤肿瘤化合物及其应用
CN113620874B (zh) * 2021-08-10 2024-02-06 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基-喹啉衍生物及其用途
CN114436975B (zh) * 2022-01-26 2023-10-31 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2-三氟甲基-4-氨基喹唑啉类化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
BR0111377A (pt) 2000-06-06 2003-06-03 Pfizer Prod Inc Derivados de tiofeno úteis como agentes anticancerìgenos
GB0126433D0 (en) 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
CA2545340A1 (en) * 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
AP2006003619A0 (en) * 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
AU2006204052A1 (en) 2005-01-03 2006-07-13 Cytovia, Inc. Method of treating brain cancer
GB0508717D0 (en) 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
WO2007034143A1 (en) * 2005-09-20 2007-03-29 Astrazeneca Ab Quinazoline derivatives as anticancer agents
FR2914640B1 (fr) 2007-04-04 2012-11-16 Centre Nat Rech Scient Iso ca-4 et analogues : puissants cytotoxiques, inhibiteurs de polymerisation de la tubuline

Also Published As

Publication number Publication date
US11634405B2 (en) 2023-04-25
US20230203005A1 (en) 2023-06-29
AU2019259112B2 (en) 2024-02-08
JP2021522244A (ja) 2021-08-30
WO2019207257A1 (fr) 2019-10-31
AU2019259112A1 (en) 2020-11-26
WO2019207257A8 (fr) 2019-11-21
EP3784662A1 (fr) 2021-03-03
FR3080620A1 (fr) 2019-11-01
FR3080620B1 (fr) 2021-11-12
US12371417B2 (en) 2025-07-29
EP3784662B1 (fr) 2022-11-09
US20210230140A1 (en) 2021-07-29
DK3784662T3 (da) 2022-12-19
CA3097622A1 (fr) 2019-10-31
JP7408894B2 (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
ES2732230T3 (es) Compuestos que anulan el punto de control G2 del ciclo celular para una utilización en el tratamiento del cáncer
US12371417B2 (en) Compounds with tubulin polymerisation inhibitory activity and immunomodulatory properties
ES2415163T3 (es) Derivados de triazina, composiciones que contienen tales derivados, y métodos de tratamiento de cáncer y enfermedades autoinmunitarias usando tales derivados
BR112020013672A2 (pt) compostos, composições, e métodos para tratamento de doenças que envolvem tecidos afetados por ácidos ou hipoxia
JP5922584B2 (ja) 結腸および胃の腺癌の処置に使用のための３−（インドリル）−または３−（アザインドリル）−４−アリールマレイミド誘導体
CN102241674A (zh) 1,1-二甲基-β-咔啉-3-甲酰基氨基酸苄酯的合成和抗肿瘤活性评价
US10851054B2 (en) Derivatives of indole for the treatment of cancer, viral infections and lung diseases
TW200836632A (en) Cyclohexylamino benzene, pyridine, and pyridazine derivatives
TW201831191A (zh) 一種新的硼酸衍生物及其藥物組合物
JP2016500080A (ja) ビスβ−カルボリン系化合物、その製造方法、医薬組成物および用途
ES2385850T3 (es) Potenciador de radioterapia
ES2849153T3 (es) 2H-Selenofeno[3,2-h]cromenos antimetastásicos, síntesis de los mismos, y métodos de uso de tales agentes
ES2900362T3 (es) Compuestos "multidiana" con actividad inhibidora de las histona-desacetilasas y de la polimerización de la tubulina para su utilización en el tratamiento del cáncer
ES2782113T3 (es) Compuestos de quinolina fusionados como inhibidores de PI3K/mTor
JP2013514295A (ja) ３−（インドリル）−または３−（アザインドリル）−４−アリールマレイミド化合物および腫瘍処置におけるそれらの使用
CN101365461B (zh) 舒林酸衍生物、其用途和其制备
JP2014500283A (ja) 共役３−（インドリル）−および３−（アザインドリル）−４−アリールマレイミド化合物および腫瘍処置におけるそれらの使用
CN103002899A (zh) 作为pi3k抑制剂用于治疗抗增殖障碍的哌嗪子基三嗪化合物
JP2017509672A (ja) 抗腫瘍化合物としてのシグマ−２受容体リガンド薬物結合体、その合成法及び使用
CN110903310B (zh) 一种硼酸酯类药物及其用途
ES2810857T3 (es) Derivados de z)-2-(1h-indol-3-il)-3-(isoquinolin-5-il)acrilonitrilo y compuestos relacionados con actividad inhibitoria de lisosoma y antimitótica para el tratamiento de enfermedades hiperproliferativas
AU2016226036B2 (en) Salicylate inhibitors of MELK and methods of use
KR20150109540A (ko) 미토콘드리아 표적화된 항-종양 조성물
ES2911229T3 (es) Compuestos de 1,2,3',5'-tetrahidro-2'H-espiro[indol-3,1'-pirrolo[3,4-c]pirrol]-2,3'-diona como agentes terapéuticos activadores de tp53
CA3233398A1 (en) Small molecule inhibitors of oncogenic chd1l with preclinical activity against colorectal cancer